Landmark phase 3 trials reveal Pfizer and BioNTech's experimental COVID-19 vaccine is 90% effective at preventing infections, as announced by the companies. While promising, some details remain under review. Here's what the data shows.
This breakthrough has sparked global optimism, signaling hope amid the pandemic. Developed by U.S.-based Pfizer and Germany's BioNTech, the vaccine demonstrated 90% efficacy in interim results from an ongoing phase 3 trial. The companies plan to seek emergency use authorization from the FDA, with potential availability by late December pending approval.
Experts worldwide applaud the progress but emphasize the need for full peer-reviewed data before widespread conclusions.
Known as BNT162b2, this mRNA-based vaccine – similar to Moderna's – uses lipid nanoparticles to deliver SARS-CoV-2 spike protein mRNA into cells. Cells read this code, produce the protein, and prime the immune system to recognize and neutralize the virus.
Earlier trials confirmed robust immune responses with no serious side effects. Common mild reactions included injection-site pain, fatigue, headaches, muscle aches, and fever.
Notably, antibody levels exceeded those in COVID-19 survivors, and strong T-cell responses suggest potential for lasting protection.
Launched July 27, 2020, the trial enrolled 43,538 participants across the U.S., Argentina, Brazil, South Africa, Germany, and Turkey. Participants were split: 38,955 received two doses 21 days apart; others got a placebo.
Efficacy was assessed seven days post-second dose (28 days total). The 90%+ rate stemmed from analyzing 94 COVID-19 cases, comparing infections in vaccine vs. placebo groups.
While encouraging, gaps persist: efficacy against severe or fatal cases is unclear, as is prevention of asymptomatic infections. Duration of protection and long-term safety remain under study.
Data submission for peer-reviewed publication is underway. Pfizer-BioNTech aim for 50 million doses in 2020 and 1.3 billion in 2021 globally.
